Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

Published:2010-11-05 Issue:12 Volume:51 Page:2222-2229
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Shanafelt Tait,Zent Clive,Byrd John,Erlichman Charles,Laplant Betsy,Ghosh Asish,Call Timothy,Villalona-Calero Miguel,Jelinek Diane,Bowen Deborah,Laumann Kristina,Wu Wenting,Hanson Curtis,Kay Neil

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2010.524327

Reference36 articles.

1. The Hallmarks of Cancer

2. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas

3. The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia

4. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

5. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation and function of angiogenic factors in chronic lymphocytic leukemia;Journal of Cancer Metastasis and Treatment;2021

2. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy;Angiogenesis;2020-05-25

3. Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets;Frontiers in Immunology;2018-01-17

4. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia;Oncotarget;2016-11-16

5. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells;Blood;2016-08-18